EASL – AASLD JOINT MEETING
Definition, therapeutic advances and clinical endpoints in alcoholic liver disease and alcoholic hepatitis

London, United Kingdom
30 September, 1 October 2017

Organising Committee:
Philippe Mathurin, Lille, France
Vijay Shah, Rochester, United States
Gyongyi Szabo, Worcester, United States
Mark Thursz, London, United Kingdom

Friday 29 September 2017
Time TBD Expert Panellists workshop

Saturday 30 September 2017
07:30 – 08:50 Registration
08:50 – 09:00 Welcome and opening remarks Gyongyi Szabo and Philippe Mathurin

Session 1: Epidemiology and progression factor of ALD
Chair: Richard Horton, London, United Kingdom
09:00 – 09:20 Burden and epidemiology of alcohol-related liver diseases Including drinking patterns in Europe and in the US
David Leon, London, United Kingdom
09:20 – 09:40 Put us out of business: Role of health policy in controlling alcohol consumption
Sir Ian Gilmore, Liverpool, United Kingdom
09:40 – 10:00 Genetics of ALD: What do we learn from the risk loci about the disease?
Jochen Hampe, Dresden, Germany
10:00 – 10:15 Discussion
10:15 – 10:35 Coffee break and ePoster session 1

Session 2: Translational science in ALD
Chair: Vijay Shah, Rochester, United States
10:35 – 10:55 Alcohol metabolism and cellular consequences
Laura Nagy, Cleveland, United States
10:55 – 11:15  From microbiome to intestinal inflammation in ALD  
*Bernd Schnabl, New York, United States*

11:15 – 11:50 Discussion

11:50 – 13:15 Lunch and ePoster session 2+3

13:15 – 13:35 Inflammation as a driver of ALD  
*Gyongyi Szabo, Worcester, United States*

13:35 – 13:55 Alcohol related fibrogenesis  
*Christian Trautwein, Aachen, Germany*

13:55 – 14:15 Impaired pathways of liver regeneration in chronic liver disease: future therapeutic target for severe ALD?  
*Anna Mae Diehl, Durham, United States*

14:15 – 14:35 Animal models of ALD and alcoholic hepatitis  
I favour the NIAAA model for targeting the key therapeutic pathway  
*Bin Gao, Washington, United States*

14:35 – 14:55 I favour the intragastric fat/alcohol model or targeting the key therapeutic pathway  
*Hidekazu Tsukamoto, Los Angeles, United States*

14:55 – 15:10 Discussion

15:10 – 15:30 Coffee break and ePoster session 4

**Session 3: Clinical challenges in the management of patients with ALD**  
Chair: Gyongyi Szabo, Worcester, United States

15:30 – 15:45 Alcohol use disorder: diagnosis  
*TBD Adolorato?*

15:45 – 16:00 Alcohol use disorder: management  
*Antoni Gual, Barcelona, Spain*

16:00 – 16:20 Assessing co-factors in ALD  
*Arun Sanyal, Richmond, United States*

16:20 – 16:35 Liver histology and AH/ALD-what is its role?  
*Dina Tiniakos, Newcastle, United Kingdom*

16:35 – 16:55 Liquid biopsy and biomarkers as a diagnostic measure and surrogate end-point  
*Vijay Shah, Rochester, United States*

16:55 – 17:15 Non-invasive assessment including imaging in early versus advanced ALD  
*Laurent Castera, Clichy, France*

17:15 – 17:30 Discussion

17:30 – 18:00 *Michael Karin, San Diego, United States*
Sunday 1 October 2017

Session 4: Management and treatment of severe form of AH  
Chair: John O’Grady, London, United Kingdom

08:00 – 08:20  
Acute AH: Defining disease severity (severe vs. moderate AH) and prognostic models of lethality and survival  
Patrick Kamath, Rochester, United States

08:20 – 08:40  
SIRS and management of infection in AH  
Ramon Bataller, Chapel Hill, United States

08:40 – 8:55  
Early liver transplantation in AH – Pro and Con debate:  
I do not favour broader use of early liver transplantation for AH  
Michael Lucey, Madison, United States

8:55 - 9:10  
I favour broader use of early liver transplantation in AH  
Philippe Mathurin, Lille, France

09:10 – 09:30  
Post-transplant complications/what is specific for ALD  
Patrizia Burra, Padova, Italy

09:30 – 09:50  
Alcohol relapse after transplantation: does-it matter?  
Georges-Philippe Pageaux, Montpellier, France

09:50 – 10:05  
Discussion

10:05 – 10:25  
Coffee break and ePoster session 7

Session 5: Clinical trial design and end-points  
Chair: Giovanni Addolorato, Rome, Italy

Perspectives of agencies and industry

10:25 – 10:45  
Cost and mortality attributed to ALD  
Rehm Jürgen, Toronto, Canada

10:45 – 11:05  
Breaking the ice: Investment into translational and clinical research in alcoholic hepatitis from the NIAA perspective  
George Kunos, United States

11:05 – 11:25  
Regulatory process to validate biomarkers and end-points for drug approval: specific requirements for AH  
Christopher Leptak, United States

11:25 – 11:45  
EMA process to validate end-points for drug approval: specific requirements for AH  
Richard Vesley, EMA

11:45 – 12:05  
Discussions

12:05 – 13:15  
Lunch and ePoster Session 8
Session 6: Future development of drugs in alcoholic hepatitis: where are we?  
Chair: Laurent Castera, Clichy, France

### Perspectives of the investigators

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:15 – 13:35</td>
<td>Patient characteristics and end-points in clinical trials for early ALD</td>
<td>Helena Cortez Pinto, Lisbon, Portugal</td>
</tr>
<tr>
<td>13:35 – 13:55</td>
<td>Current treatments in alcoholic hepatitis (lessons learned) and ongoing clinical trials</td>
<td>Mark Thursz, London, United Kingdom</td>
</tr>
<tr>
<td>13:55 – 14:15</td>
<td>Clinical trial design: What is the optimal plan of development from phase I to Phase III?</td>
<td>Alexandre Louvet, Lille, France</td>
</tr>
<tr>
<td>14:15 – 14:35</td>
<td>How can large epidemiologic studies, registries and bio-banks may help in the setting of AH and ALD</td>
<td>Alexander Krag, Odense, Denmark.</td>
</tr>
<tr>
<td>14:35-14:55</td>
<td>Lessons learned from NASH CRN and DILI network on clinical networks, sample and data collection</td>
<td>Naga Chalasani, Cincinnati, United States</td>
</tr>
<tr>
<td>14:55 – 15:15</td>
<td>Which therapeutic targets will be the most attractive in the future?</td>
<td>Craig McClain, Louisville, United States</td>
</tr>
</tbody>
</table>

### Industry perspectives

<table>
<thead>
<tr>
<th>Time</th>
<th>Activity</th>
</tr>
</thead>
</table>
| 15:30-16:30 | Invite 3-4 pharma leaders to give a brief, 5-8 min overview of their plans/perspectives/challenges on clinical trials in ALD/AH  
Gilead  
Intercept  
Allergan (Tobira)  
Verlyx  
Give each 15 min (presentation+ discussion) |

| 16:30 – 16:40 | Discussions & Closing Remarks                                             |
|               | Vijay Shah and Mark Thursz                                              |

| 16:00 – 19:00 | Expert panelists workshops                                               |